Patents by Inventor James A.H. Harwick

James A.H. Harwick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Topical formulations and treatments
    Patent number: 12064404
    Abstract: The present invention provides topical dosages and formulations of lidocaine and pharmaceutically acceptable salts thereof, which are efficacious, chemically stable and physiologically balanced for safety and efficacy, particularly for debridement pain, and increase the duration of pain relief, and thereby provide more effective treatment to chronic open wounds, particularly those in non-mucosal tissue.
    Type: Grant
    Filed: September 6, 2022
    Date of Patent: August 20, 2024
    Inventors: Hemant H. Alur, James A H Harwick
  • Topical formulations and treatments
    Patent number: 11458113
    Abstract: The present invention provides topical dosages and formulations of lidocaine and pharmaceutically acceptable salts thereof, which are efficacious, chemically stable and physiologically balanced for safety and efficacy, particularly for debridement pain, and increase the duration of pain relief, and thereby provide more effective treatment to chronic open wounds, particularly those in non-mucosal tissue.
    Type: Grant
    Filed: July 7, 2019
    Date of Patent: October 4, 2022
    Assignee: Trilogic Pharma LLC
    Inventors: Hemant H. Alur, James A H Harwick
  • TOPICAL FORMULATIONS AND TREATMENTS
    Publication number: 20220040306
    Abstract: Provided is a pharmaceutical formulation and a method associated therewith for treating bacterial vaginosis. The pharmaceutical formulation includes from 10 to 25 weight parts of poloxamer F127, from 0.5 to 3.0 weight parts of xanthan gum, from 70 to 90 weight parts of water, and a therapeutically effective amount of a pharmaceutical active ingredient. The pharmaceutical formulation may also include from 0.5 to 1.5 weight parts of benzyl alcohol.
    Type: Application
    Filed: August 23, 2021
    Publication date: February 10, 2022
    Inventors: Hemant H. ALUR, James A. H. Harwick
  • Topical formulations and treatments
    Patent number: 11129896
    Abstract: Provided is a pharmaceutical formulation and a method associated therewith for treating bacterial vaginosis. The pharmaceutical formulation includes from 10 to 25 weight parts of poloxamer F127, from 0.5 to 3.0 weight parts of xanthan gum, from 70 to 90 weight parts of water, and a therapeutically effective amount of a pharmaceutical active ingredient. The pharmaceutical formulation may also include from 0.5 to 1.5 weight parts of benzyl alcohol.
    Type: Grant
    Filed: July 18, 2016
    Date of Patent: September 28, 2021
    Assignee: Trilogic Pharma LLC
    Inventors: Hemant H. Alur, James A. H. Harwick
  • Topical formulations and treatments
    Patent number: 10383833
    Abstract: The present invention provides topical dosages and formulations of lidocaine and pharmaceutically acceptable salts thereof, which are efficacious, chemically stable and physiologically balanced for safety and efficacy, particularly for debridement pain, and increase the duration of pain relief, and thereby provide more effective treatment to chronic open wounds, particularly those in non-mucosal tissue.
    Type: Grant
    Filed: October 9, 2017
    Date of Patent: August 20, 2019
    Assignee: Milanapharm LLC
    Inventors: Hemant H Alur, James A H Harwick
  • Bioadhesive compositions for epithelial drug delivery
    Patent number: 10039709
    Abstract: Disclosed are compositions and methods for treating a disease, such as infection, pain, or inflammation, by using the compositions. Particularly, disclosed is a method of treating oral pain, wherein, the above-described compositions are applied to the oral mucosa; the compositions undergo in-situ gelation, optimal adhesion to the oral mucosa, controlled erosion and controlled release of the active ingredient, i.e., benzocaine, which provides a superior degree of pain relief or analgesia for an extended period of time.
    Type: Grant
    Filed: June 2, 2011
    Date of Patent: August 7, 2018
    Assignee: TRILOGIC PHARMA LLC
    Inventors: Hemant H. Alur, James A. H. Harwick, Mondal Pravakar, Thomas P. Johnston
  • TOPICAL FORMULATIONS AND TREATMENTS
    Publication number: 20180207275
    Abstract: Provided is a pharmaceutical formulation and a method associated therewith for treating bacterial vaginosis. The pharmaceutical formulation includes from 10 to 25 weight parts of poloxamer F127, from 0.5 to 3.0 weight parts of xanthan gum, from 70 to 90 weight parts of water, and a therapeutically effective amount of a pharmaceutical active ingredient. The pharmaceutical formulation may also include from 0.5 to 1.5 weight parts of benzyl alcohol.
    Type: Application
    Filed: July 18, 2016
    Publication date: July 26, 2018
    Inventors: Hemant H. ALUR, James A. H. Harwick
  • Self solidifying bioerodible barrier implant
    Patent number: 8691278
    Abstract: Provided are bioerodible compositions that can be implanted into cavities or mammalian tissue as a liquid or semi-liquid and which solidify upon exposure of the body temperature of the mammal. The implants erode over a prescribed period of time and elute a drug. The implants also form a seal with the skin or mucosa surrounding the cavity to prevent the entry of bacterial pathogens.
    Type: Grant
    Filed: July 12, 2013
    Date of Patent: April 8, 2014
    Assignee: Trilogic Pharma LLC
    Inventors: Hemant H. Alur, James A. H. Harwick, Pravakar Mondal, Thomas P. Johnston
  • SELF SOLIDIFYING BIOERODIBLE BARRIER IMPLANT
    Publication number: 20130338088
    Abstract: Provided are bioerodible compositions that can be implanted into cavities or mammalian tissue as a liquid or semi-liquid and which solidify upon exposure of the body temperature of the mammal. The implants erode over a prescribed period of time and elute a drug. The implants also form a seal with the skin or mucosa surrounding the cavity to prevent the entry of bacterial pathogens.
    Type: Application
    Filed: July 12, 2013
    Publication date: December 19, 2013
    Applicant: TriLobic Pharma LLC
    Inventors: Hemant H. Alur, James A.H. Harwick, Pravakar Mondal, Thomas P. Johnston
  • Self solidifying bioerodible barrier implant
    Patent number: 8501230
    Abstract: Provided are bioerodible compositions that can be implanted into cavities of mammalian tissue as a liquid or semi-liquid and which solidify upon exposure to body temperature of the mammal. The implants erode over a prescribed period of time and elute a drug. The implants also form a seal with the skin or mucosa surrounding the cavity to prevent the entry of bacterial pathogens.
    Type: Grant
    Filed: December 2, 2008
    Date of Patent: August 6, 2013
    Assignee: TriLogic Pharma LLC
    Inventors: Hemant H. Alur, James A. H. Harwick, Pravakar Mondal, Thomas P. Johnston
  • BIOADHESIVE COMPOSITIONS FOR EPITHELIAL DRUG DELIVERY
    Publication number: 20130131166
    Abstract: Disclosed are compositions and methods for treating a disease, such as infection, pain, or inflammation, by using the compositions. Particularly, disclosed is a method of treating oral pain, wherein, the above-described compositions are applied to the oral mucosa; the compositions undergo in-situ gelation, optimal adhesion to the oral mucosa, controlled erosion and controlled release of the active ingredient, i.e., benzocaine, which provides a superior degree of pain relief or analgesia for an extended period of time.
    Type: Application
    Filed: June 2, 2011
    Publication date: May 23, 2013
    Applicant: TRILOGIC PHARMA LLC
    Inventors: Hemant H. Alur, James A.H. Harwick, Mondal Pravakar, Thomas P. Johnston
  • Self Solidifying Bioerodible Barrier Implant
    Publication number: 20100324110
    Abstract: Provided are bioerodible compositions that can be implanted into cavities of mammalian tissue as a liquid or semi-liquid and which solidify upon exposure to body temperature of the mammal. The implants erode over a prescribed period of time and elute a drug. The implants also form a seal with the skin or mucosa surrounding the cavity to prevent the entry of bacterial pathogens.
    Type: Application
    Filed: December 2, 2008
    Publication date: December 23, 2010
    Applicant: TriLogic Pharma LLC
    Inventors: Hemant H. Alur, James A.H. Harwick, Pravakar Mondal, Thomas P. Johnston